[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$flt1x8_meWsjNw-TW9qdQj51T0IXge7HMWQPnf1aYviQ":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":81,"rows":88},"University of Saskatchewan",[4],240,false,24,17,23071,11,157,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Asthma",20,{"name":18,"count":19},"Osteoporosis",10,{"name":21,"count":22},"Sarcopenia",7,{"name":24,"count":22},"Pain",{"name":26,"count":27},"Coronary Artery Disease",6,{"name":29,"count":30},"Depression",5,{"name":32,"count":33},"Multiple Sclerosis",4,{"name":35,"count":33},"Hypertension",[37,42,47,52,56,61,66,71,76],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06574100","Relative Bioavailability of Two Orally Administered CBD Formulations in Healthy Male Adults","2025-11","Cannabidiol",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03272698","ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression","2025-12-31","Ketamine",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT04459065","Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery","2026-09","IRDye800CW-nimotuzumab",{"nctId":53,"briefTitle":54,"date":50,"intervention":55},"NCT04235114","Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)","50 mg 89Zr-DFO-Nimotuzumab",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT03401294","Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.","2026-12-31","FOLFOXIRI and Bevacizumab",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT06679465","Evaluating the Impact of Single Dose Tiotropium on Allergen-induced Early Asthmatic Response","2027-01","Tiotropium",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06047015","Irreversible Electroporation (NanoKnife ®) and Immunotherapy for the Treatment of Stage IV Colorectal Cancer","2027-12","IRE plus checkpoint inhibitor",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06248749","Effect of Intravenously Iron Infusion on the Prevention and Treatment of Anemia in Ovarian Cancer","2028-12-01","IV iron",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT07178678","Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease","2030-03","NeuroEPO",[82,83,84,85,86,87],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[89,136,167,189,212,230,252,273,295,318,336,356,408,446,480,510,540,562,595,622,640,658,676,700,730,755,773,798,829,847,865,883,910,928,946,964,989,1007,1025,1050,1078,1103,1121,1146,1169,1187,1205,1228,1251,1279,1304,1322,1347,1376,1440,1458,1484,1514,1532,1550,1568,1586,1604,1622,1640,1658,1686,1704,1722,1740,1758,1776,1802,1865,1891,1917,1946,1969,1993,2017,2039,2064,2082,2106,2130,2160,2178,2208,2241,2277,2312,2338,2356,2379,2404,2422,2440,2458,2482,2500,2524,2550,2568,2592,2610,2628,2652,2679,2704,2722,2745,2768,2790,2814,2842,2860],{"intervention":46,"totalTrials":90,"cells":91},3,{"EARLY_PHASE1":92,"PHASE1":95,"PHASE2":97,"PHASE3":99,"PHASE4":113,"NA":134},{"trials":93,"activeCount":94},[],0,{"trials":96,"activeCount":94},[],{"trials":98,"activeCount":94},[],{"trials":100,"activeCount":94},[101],{"nctId":102,"briefTitle":103,"status":104,"phases":105,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":109,"interventions":111},"NCT02514122","Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda","COMPLETED",[84,85],"2015-07","2015-06",61,[110,24],"Post Operative Pain",[46,112],"Saline",{"trials":114,"activeCount":133,"soonestReadout":45},[115,123],{"nctId":43,"briefTitle":44,"status":116,"phases":117,"primaryCompletion":45,"completion":45,"start":118,"enrollment":119,"conditions":120,"interventions":122},"RECRUITING",[86],"2017-09-01",62,[121,46],"Treatment Resistant Depression",[46],{"nctId":124,"briefTitle":125,"status":104,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":131},"NCT01935115","Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy",[86],"2016-03","2013-09",27,[121],[132,46],"Propofol",1,{"trials":135,"activeCount":94},[],{"intervention":65,"totalTrials":137,"cells":138},2,{"EARLY_PHASE1":139,"PHASE1":141,"PHASE2":143,"PHASE3":145,"PHASE4":147,"NA":165},{"trials":140,"activeCount":94},[],{"trials":142,"activeCount":94},[],{"trials":144,"activeCount":94},[],{"trials":146,"activeCount":94},[],{"trials":148,"activeCount":133,"soonestReadout":64},[149,158],{"nctId":150,"briefTitle":151,"status":104,"phases":152,"primaryCompletion":127,"completion":127,"start":153,"enrollment":154,"conditions":155,"interventions":156},"NCT02622243","Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge",[86],"2015-11",13,[15],[65,157],"glycopyrronium",{"nctId":62,"briefTitle":63,"status":159,"phases":160,"primaryCompletion":64,"completion":64,"start":161,"enrollment":19,"conditions":162,"interventions":164},"NOT_YET_RECRUITING",[86],"2025-01-01",[163],"Asthma Bronchiale",[65],{"trials":166,"activeCount":94},[],{"intervention":75,"totalTrials":133,"cells":168},{"EARLY_PHASE1":169,"PHASE1":171,"PHASE2":173,"PHASE3":175,"PHASE4":185,"NA":187},{"trials":170,"activeCount":94},[],{"trials":172,"activeCount":94},[],{"trials":174,"activeCount":94},[],{"trials":176,"activeCount":133,"soonestReadout":74},[177],{"nctId":72,"briefTitle":73,"status":159,"phases":178,"primaryCompletion":74,"completion":179,"start":180,"enrollment":181,"conditions":182,"interventions":184},[85],"2029-12-01","2024-02-29",200,[183],"Anaemia in Ovarian Carcinoma",[75],{"trials":186,"activeCount":94},[],{"trials":188,"activeCount":94},[],{"intervention":70,"totalTrials":133,"cells":190},{"EARLY_PHASE1":191,"PHASE1":193,"PHASE2":195,"PHASE3":206,"PHASE4":208,"NA":210},{"trials":192,"activeCount":94},[],{"trials":194,"activeCount":94},[],{"trials":196,"activeCount":133,"soonestReadout":69},[197],{"nctId":67,"briefTitle":68,"status":159,"phases":198,"primaryCompletion":69,"completion":199,"start":200,"enrollment":201,"conditions":202,"interventions":204},[83,84],"2028-12","2025-07",12,[203],"Liver Metastasis Colon Cancer",[70,205],"IRE plus Checkpoint Inhibitor plus CpG-ODN",{"trials":207,"activeCount":94},[],{"trials":209,"activeCount":94},[],{"trials":211,"activeCount":94},[],{"intervention":205,"totalTrials":133,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":215,"activeCount":94},[],{"trials":217,"activeCount":94},[],{"trials":219,"activeCount":133,"soonestReadout":69},[220],{"nctId":67,"briefTitle":68,"status":159,"phases":221,"primaryCompletion":69,"completion":199,"start":200,"enrollment":201,"conditions":222,"interventions":223},[83,84],[203],[70,205],{"trials":225,"activeCount":94},[],{"trials":227,"activeCount":94},[],{"trials":229,"activeCount":94},[],{"intervention":51,"totalTrials":133,"cells":231},{"EARLY_PHASE1":232,"PHASE1":234,"PHASE2":236,"PHASE3":246,"PHASE4":248,"NA":250},{"trials":233,"activeCount":94},[],{"trials":235,"activeCount":94},[],{"trials":237,"activeCount":133,"soonestReadout":50},[238],{"nctId":48,"briefTitle":49,"status":116,"phases":239,"primaryCompletion":50,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":245},[83,84],"2026-10","2020-09-01",36,[244],"Lung Cancer",[51],{"trials":247,"activeCount":94},[],{"trials":249,"activeCount":94},[],{"trials":251,"activeCount":94},[],{"intervention":60,"totalTrials":133,"cells":253},{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":267,"PHASE4":269,"NA":271},{"trials":255,"activeCount":94},[],{"trials":257,"activeCount":94},[],{"trials":259,"activeCount":133,"soonestReadout":59},[260],{"nctId":57,"briefTitle":58,"status":116,"phases":261,"primaryCompletion":59,"completion":59,"start":262,"enrollment":263,"conditions":264,"interventions":266},[84],"2025-05-01",32,[265],"Metastatic Colorectal Cancer",[60],{"trials":268,"activeCount":94},[],{"trials":270,"activeCount":94},[],{"trials":272,"activeCount":94},[],{"intervention":80,"totalTrials":133,"cells":274},{"EARLY_PHASE1":275,"PHASE1":277,"PHASE2":279,"PHASE3":289,"PHASE4":291,"NA":293},{"trials":276,"activeCount":94},[],{"trials":278,"activeCount":94},[],{"trials":280,"activeCount":133,"soonestReadout":79},[281],{"nctId":77,"briefTitle":78,"status":159,"phases":282,"primaryCompletion":79,"completion":283,"start":40,"enrollment":284,"conditions":285,"interventions":288},[84],"2030-12",90,[286,287],"Mild Alzheimer's Disease","Moderate Alzheimer's Disease",[80],{"trials":290,"activeCount":94},[],{"trials":292,"activeCount":94},[],{"trials":294,"activeCount":94},[],{"intervention":55,"totalTrials":133,"cells":296},{"EARLY_PHASE1":297,"PHASE1":299,"PHASE2":301,"PHASE3":312,"PHASE4":314,"NA":316},{"trials":298,"activeCount":94},[],{"trials":300,"activeCount":94},[],{"trials":302,"activeCount":133,"soonestReadout":50},[303],{"nctId":53,"briefTitle":54,"status":116,"phases":304,"primaryCompletion":50,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},[83,84],"2026-12","2020-02-01",14,[244,309],"Colorectal Cancer",[55,311],"1 mg 89Zr-DFO-Nimotuzumab",{"trials":313,"activeCount":94},[],{"trials":315,"activeCount":94},[],{"trials":317,"activeCount":94},[],{"intervention":311,"totalTrials":133,"cells":319},{"EARLY_PHASE1":320,"PHASE1":322,"PHASE2":324,"PHASE3":330,"PHASE4":332,"NA":334},{"trials":321,"activeCount":94},[],{"trials":323,"activeCount":94},[],{"trials":325,"activeCount":133,"soonestReadout":50},[326],{"nctId":53,"briefTitle":54,"status":116,"phases":327,"primaryCompletion":50,"completion":305,"start":306,"enrollment":307,"conditions":328,"interventions":329},[83,84],[244,309],[55,311],{"trials":331,"activeCount":94},[],{"trials":333,"activeCount":94},[],{"trials":335,"activeCount":94},[],{"intervention":41,"totalTrials":133,"cells":337},{"EARLY_PHASE1":338,"PHASE1":340,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":339,"activeCount":94},[],{"trials":341,"activeCount":133,"soonestReadout":40},[342],{"nctId":38,"briefTitle":39,"status":116,"phases":343,"primaryCompletion":40,"completion":40,"start":344,"enrollment":16,"conditions":345,"interventions":347},[83],"2024-10-26",[346],"Pharmacokinetics",[41,41],{"trials":349,"activeCount":94},[],{"trials":351,"activeCount":94},[],{"trials":353,"activeCount":94},[],{"trials":355,"activeCount":94},[],{"intervention":357,"totalTrials":90,"cells":358},"Placebos",{"EARLY_PHASE1":359,"PHASE1":361,"PHASE2":363,"PHASE3":365,"PHASE4":367,"NA":406},{"trials":360,"activeCount":94},[],{"trials":362,"activeCount":94},[],{"trials":364,"activeCount":94},[],{"trials":366,"activeCount":94},[],{"trials":368,"activeCount":94},[369,382,396],{"nctId":370,"briefTitle":371,"status":104,"phases":372,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":377,"interventions":379},"NCT03207438","Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression",[86],"2007-07","2019-10","2006-04",1790,[378],"Depressive Disorder, Major",[380,381,357],"Quetiapine 50 MG Extended Release Oral","Quetiapine Fumarate XR 150-300 mg",{"nctId":383,"briefTitle":384,"status":104,"phases":385,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":390,"interventions":395},"NCT02989727","Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine",[86],"2005-08","2017-12","2003-11",150,[29,391,392,393,394],"Bipolar Disorder","Bipolar Depression","Melancholia","Lamotrigine",[394,357],{"nctId":397,"briefTitle":398,"status":104,"phases":399,"primaryCompletion":400,"completion":400,"start":401,"enrollment":9,"conditions":402,"interventions":403},"NCT03315000","Effect of Vilanterol on Methacholine Challenge Results",[86],"2018-05-01","2017-10-13",[15],[404,405,357],"Vilanterol and Fluticasone Furoate","Fluticasone Furoate",{"trials":407,"activeCount":94},[],{"intervention":409,"totalTrials":137,"cells":410},"Dexmedetomidine",{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":431,"NA":444},{"trials":412,"activeCount":94},[],{"trials":414,"activeCount":94},[],{"trials":416,"activeCount":94},[],{"trials":418,"activeCount":94},[419],{"nctId":420,"briefTitle":421,"status":104,"phases":422,"primaryCompletion":153,"completion":153,"start":107,"enrollment":423,"conditions":424,"interventions":426},"NCT02466022","Dexmedetomidine for Sedation in Total Knee Replacements",[85],54,[425],"Post-operative Pain for Total Knee Arthroplasty",[409,427,428,429,430],"Bupivicaine","Normal Saline","Fentanyl","Midazolam",{"trials":432,"activeCount":94},[433],{"nctId":434,"briefTitle":435,"status":104,"phases":436,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":440,"interventions":442},"NCT02026141","Can Dexmedetomidine For Procedural Sedation In Knee Arthroplasty Reduce Postoperative Pain? A Randomized Control Study",[86],"2014-06","2013-12",40,[441],"Total Knee Arthroplasty",[409,443],"Normal Saline Placebo",{"trials":445,"activeCount":94},[],{"intervention":447,"totalTrials":137,"cells":448},"salbutamol",{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":457,"NA":478},{"trials":450,"activeCount":94},[],{"trials":452,"activeCount":94},[],{"trials":454,"activeCount":94},[],{"trials":456,"activeCount":94},[],{"trials":458,"activeCount":94},[459,469],{"nctId":460,"briefTitle":461,"status":104,"phases":462,"primaryCompletion":463,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":468},"NCT00440245","Bronchoprotection of Salbutamol in Asthma and Chronic Obstructive Pulmonary Disease",[86],"2010-07","2007-02",28,[15,467],"COPD",[447],{"nctId":470,"briefTitle":471,"status":104,"phases":472,"primaryCompletion":473,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":477},"NCT01338311","Salbutamol Tolerance Onset",[86],"2012-03","2011-03",15,[15],[447],{"trials":479,"activeCount":94},[],{"intervention":157,"totalTrials":137,"cells":481},{"EARLY_PHASE1":482,"PHASE1":484,"PHASE2":486,"PHASE3":488,"PHASE4":490,"NA":508},{"trials":483,"activeCount":94},[],{"trials":485,"activeCount":94},[],{"trials":487,"activeCount":94},[],{"trials":489,"activeCount":94},[],{"trials":491,"activeCount":94},[492,496],{"nctId":150,"briefTitle":151,"status":104,"phases":493,"primaryCompletion":127,"completion":127,"start":153,"enrollment":154,"conditions":494,"interventions":495},[86],[15],[65,157],{"nctId":497,"briefTitle":498,"status":104,"phases":499,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":505},"NCT02953041","Effect of a LAMA and a uLABA on the Methacholine Dose-response Curve",[86],"2017-01","2017-01-09","2016-10",31,[15],[506,507],"Glycopyrronium","Indacaterol",{"trials":509,"activeCount":94},[],{"intervention":132,"totalTrials":137,"cells":511},{"EARLY_PHASE1":512,"PHASE1":514,"PHASE2":516,"PHASE3":518,"PHASE4":520,"NA":538},{"trials":513,"activeCount":94},[],{"trials":515,"activeCount":94},[],{"trials":517,"activeCount":94},[],{"trials":519,"activeCount":94},[],{"trials":521,"activeCount":94},[522,534],{"nctId":523,"briefTitle":524,"status":525,"phases":526,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":532},"NCT03666494","Ketamine Co-induction for Patients With Major Depressive Disorder","UNKNOWN",[86],"2019-12","2018-12",50,[46,29,531],"Anesthesia",[533,132,429],"Ketamine Hydrochloride",{"nctId":124,"briefTitle":125,"status":104,"phases":535,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":536,"interventions":537},[86],[121],[132,46],{"trials":539,"activeCount":94},[],{"intervention":429,"totalTrials":137,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":548,"PHASE4":554,"NA":560},{"trials":543,"activeCount":94},[],{"trials":545,"activeCount":94},[],{"trials":547,"activeCount":94},[],{"trials":549,"activeCount":94},[550],{"nctId":420,"briefTitle":421,"status":104,"phases":551,"primaryCompletion":153,"completion":153,"start":107,"enrollment":423,"conditions":552,"interventions":553},[85],[425],[409,427,428,429,430],{"trials":555,"activeCount":94},[556],{"nctId":523,"briefTitle":524,"status":525,"phases":557,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":558,"interventions":559},[86],[46,29,531],[533,132,429],{"trials":561,"activeCount":94},[],{"intervention":563,"totalTrials":137,"cells":564},"Methacholine",{"EARLY_PHASE1":565,"PHASE1":567,"PHASE2":569,"PHASE3":571,"PHASE4":583,"NA":593},{"trials":566,"activeCount":94},[],{"trials":568,"activeCount":94},[],{"trials":570,"activeCount":94},[],{"trials":572,"activeCount":94},[573],{"nctId":574,"briefTitle":575,"status":104,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT03505489","The Effect of Deep Inhalation on Mannitol Responsiveness",[85],"2019-04-30","2018-06-01",26,[15],[563,582],"Mannitol",{"trials":584,"activeCount":94},[585],{"nctId":586,"briefTitle":587,"status":104,"phases":588,"primaryCompletion":589,"completion":589,"start":590,"enrollment":16,"conditions":591,"interventions":592},"NCT01642745","Mannitol (Aridol) and Methacholine (Provocholine) Responsiveness",[86],"2013-02","2011-11",[15],[563,582,563],{"trials":594,"activeCount":94},[],{"intervention":405,"totalTrials":137,"cells":596},{"EARLY_PHASE1":597,"PHASE1":599,"PHASE2":601,"PHASE3":603,"PHASE4":605,"NA":620},{"trials":598,"activeCount":94},[],{"trials":600,"activeCount":94},[],{"trials":602,"activeCount":94},[],{"trials":604,"activeCount":94},[],{"trials":606,"activeCount":94},[607,611],{"nctId":397,"briefTitle":398,"status":104,"phases":608,"primaryCompletion":400,"completion":400,"start":401,"enrollment":9,"conditions":609,"interventions":610},[86],[15],[404,405,357],{"nctId":612,"briefTitle":613,"status":104,"phases":614,"primaryCompletion":615,"completion":615,"start":616,"enrollment":307,"conditions":617,"interventions":618},"NCT03898466","Effect of Fluticasone Furoate on Methacholine Challenge",[86],"2019-04-01","2018-10-30",[15],[619],"Fluticasone furoate",{"trials":621,"activeCount":94},[],{"intervention":380,"totalTrials":133,"cells":623},{"EARLY_PHASE1":624,"PHASE1":626,"PHASE2":628,"PHASE3":630,"PHASE4":632,"NA":638},{"trials":625,"activeCount":94},[],{"trials":627,"activeCount":94},[],{"trials":629,"activeCount":94},[],{"trials":631,"activeCount":94},[],{"trials":633,"activeCount":94},[634],{"nctId":370,"briefTitle":371,"status":104,"phases":635,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":636,"interventions":637},[86],[378],[380,381,357],{"trials":639,"activeCount":94},[],{"intervention":381,"totalTrials":133,"cells":641},{"EARLY_PHASE1":642,"PHASE1":644,"PHASE2":646,"PHASE3":648,"PHASE4":650,"NA":656},{"trials":643,"activeCount":94},[],{"trials":645,"activeCount":94},[],{"trials":647,"activeCount":94},[],{"trials":649,"activeCount":94},[],{"trials":651,"activeCount":94},[652],{"nctId":370,"briefTitle":371,"status":104,"phases":653,"primaryCompletion":373,"completion":374,"start":375,"enrollment":376,"conditions":654,"interventions":655},[86],[378],[380,381,357],{"trials":657,"activeCount":94},[],{"intervention":443,"totalTrials":133,"cells":659},{"EARLY_PHASE1":660,"PHASE1":662,"PHASE2":664,"PHASE3":666,"PHASE4":668,"NA":674},{"trials":661,"activeCount":94},[],{"trials":663,"activeCount":94},[],{"trials":665,"activeCount":94},[],{"trials":667,"activeCount":94},[],{"trials":669,"activeCount":94},[670],{"nctId":434,"briefTitle":435,"status":104,"phases":671,"primaryCompletion":437,"completion":437,"start":438,"enrollment":439,"conditions":672,"interventions":673},[86],[441],[409,443],{"trials":675,"activeCount":94},[],{"intervention":677,"totalTrials":133,"cells":678},"tiotropium bromide monohydrate",{"EARLY_PHASE1":679,"PHASE1":681,"PHASE2":683,"PHASE3":685,"PHASE4":687,"NA":698},{"trials":680,"activeCount":94},[],{"trials":682,"activeCount":94},[],{"trials":684,"activeCount":94},[],{"trials":686,"activeCount":94},[],{"trials":688,"activeCount":94},[689],{"nctId":690,"briefTitle":691,"status":104,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":475,"conditions":695,"interventions":697},"NCT04648813","Tiotropium Efficacy Against Allergen Induced Early Asthmatic Responses",[86],"2021-04-20","2020-11-13",[696],"Allergic Asthma",[677],{"trials":699,"activeCount":94},[],{"intervention":701,"totalTrials":133,"cells":702},"Ropivacaine",{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":709,"PHASE4":711,"NA":728},{"trials":704,"activeCount":94},[],{"trials":706,"activeCount":94},[],{"trials":708,"activeCount":94},[],{"trials":710,"activeCount":94},[],{"trials":712,"activeCount":94},[713],{"nctId":714,"briefTitle":715,"status":104,"phases":716,"primaryCompletion":717,"completion":718,"start":719,"enrollment":720,"conditions":721,"interventions":727},"NCT03588689","Continuous Fascia Iliaca Block for Acute Hip Fractures",[86],"2019-03-31","2019-05-01","2018-05-07",30,[722,723,724,725,726,24],"Hip Fractures","Neuromuscular Blockade","Respiratory Morbidity","Delirium","Fascia Iliaca Block",[701],{"trials":729,"activeCount":94},[],{"intervention":731,"totalTrials":133,"cells":732},"salbutamol aqueous solution",{"EARLY_PHASE1":733,"PHASE1":735,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":753},{"trials":734,"activeCount":94},[],{"trials":736,"activeCount":94},[],{"trials":738,"activeCount":94},[],{"trials":740,"activeCount":94},[],{"trials":742,"activeCount":94},[743],{"nctId":744,"briefTitle":745,"status":104,"phases":746,"primaryCompletion":747,"completion":747,"start":748,"enrollment":749,"conditions":750,"interventions":751},"NCT05977699","Reversibility of Methacholine Induced Bronchoconstriction",[86],"2024-11-25","2024-01-12",16,[15],[731,752],"salbutamol pressurized metered dose inhaler",{"trials":754,"activeCount":94},[],{"intervention":752,"totalTrials":133,"cells":756},{"EARLY_PHASE1":757,"PHASE1":759,"PHASE2":761,"PHASE3":763,"PHASE4":765,"NA":771},{"trials":758,"activeCount":94},[],{"trials":760,"activeCount":94},[],{"trials":762,"activeCount":94},[],{"trials":764,"activeCount":94},[],{"trials":766,"activeCount":94},[767],{"nctId":744,"briefTitle":745,"status":104,"phases":768,"primaryCompletion":747,"completion":747,"start":748,"enrollment":749,"conditions":769,"interventions":770},[86],[15],[731,752],{"trials":772,"activeCount":94},[],{"intervention":774,"totalTrials":133,"cells":775},"Apixaban",{"EARLY_PHASE1":776,"PHASE1":778,"PHASE2":780,"PHASE3":782,"PHASE4":784,"NA":796},{"trials":777,"activeCount":94},[],{"trials":779,"activeCount":94},[],{"trials":781,"activeCount":94},[],{"trials":783,"activeCount":94},[],{"trials":785,"activeCount":94},[786],{"nctId":787,"briefTitle":788,"status":104,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":307,"conditions":792,"interventions":795},"NCT04023760","Drug Interaction Study of Apixaban With Cyclosporine or Tacrolimus in Transplant Recipients",[86],"2020-03-30","2019-06-26",[346,793,794],"Kidney Transplant","Lung Transplant",[774],{"trials":797,"activeCount":94},[],{"intervention":799,"totalTrials":133,"cells":800},"Myfortic®",{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":805,"PHASE3":807,"PHASE4":809,"NA":827},{"trials":802,"activeCount":94},[],{"trials":804,"activeCount":94},[],{"trials":806,"activeCount":94},[],{"trials":808,"activeCount":94},[],{"trials":810,"activeCount":94},[811],{"nctId":812,"briefTitle":813,"status":814,"phases":815,"primaryCompletion":816,"completion":816,"start":817,"enrollment":94,"conditions":818,"interventions":823},"NCT02058875","Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring","WITHDRAWN",[86],"2015-10","2014-02",[819,820,821,822],"Cardiovascular Disease","Cardiovascular Outcomes","Kidney Transplant Recipients","Kidney Transplantation",[799,824,825,826],"Neoral®","Cellcept®","Prednisone",{"trials":828,"activeCount":94},[],{"intervention":824,"totalTrials":133,"cells":830},{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":845},{"trials":832,"activeCount":94},[],{"trials":834,"activeCount":94},[],{"trials":836,"activeCount":94},[],{"trials":838,"activeCount":94},[],{"trials":840,"activeCount":94},[841],{"nctId":812,"briefTitle":813,"status":814,"phases":842,"primaryCompletion":816,"completion":816,"start":817,"enrollment":94,"conditions":843,"interventions":844},[86],[819,820,821,822],[799,824,825,826],{"trials":846,"activeCount":94},[],{"intervention":825,"totalTrials":133,"cells":848},{"EARLY_PHASE1":849,"PHASE1":851,"PHASE2":853,"PHASE3":855,"PHASE4":857,"NA":863},{"trials":850,"activeCount":94},[],{"trials":852,"activeCount":94},[],{"trials":854,"activeCount":94},[],{"trials":856,"activeCount":94},[],{"trials":858,"activeCount":94},[859],{"nctId":812,"briefTitle":813,"status":814,"phases":860,"primaryCompletion":816,"completion":816,"start":817,"enrollment":94,"conditions":861,"interventions":862},[86],[819,820,821,822],[799,824,825,826],{"trials":864,"activeCount":94},[],{"intervention":826,"totalTrials":133,"cells":866},{"EARLY_PHASE1":867,"PHASE1":869,"PHASE2":871,"PHASE3":873,"PHASE4":875,"NA":881},{"trials":868,"activeCount":94},[],{"trials":870,"activeCount":94},[],{"trials":872,"activeCount":94},[],{"trials":874,"activeCount":94},[],{"trials":876,"activeCount":94},[877],{"nctId":812,"briefTitle":813,"status":814,"phases":878,"primaryCompletion":816,"completion":816,"start":817,"enrollment":94,"conditions":879,"interventions":880},[86],[819,820,821,822],[799,824,825,826],{"trials":882,"activeCount":94},[],{"intervention":884,"totalTrials":133,"cells":885},"Gonal F",{"EARLY_PHASE1":886,"PHASE1":888,"PHASE2":890,"PHASE3":892,"PHASE4":894,"NA":908},{"trials":887,"activeCount":94},[],{"trials":889,"activeCount":94},[],{"trials":891,"activeCount":94},[],{"trials":893,"activeCount":94},[],{"trials":895,"activeCount":94},[896],{"nctId":897,"briefTitle":898,"status":104,"phases":899,"primaryCompletion":900,"completion":900,"start":464,"enrollment":901,"conditions":902,"interventions":904},"NCT00439829","Synchronization of Follicle Wave Emergence and Ovarian Stimulation",[86],"2010-05",80,[903],"Infertility",[884,905,906,907],"Luveris","Cetrotide","hCG",{"trials":909,"activeCount":94},[],{"intervention":905,"totalTrials":133,"cells":911},{"EARLY_PHASE1":912,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":926},{"trials":913,"activeCount":94},[],{"trials":915,"activeCount":94},[],{"trials":917,"activeCount":94},[],{"trials":919,"activeCount":94},[],{"trials":921,"activeCount":94},[922],{"nctId":897,"briefTitle":898,"status":104,"phases":923,"primaryCompletion":900,"completion":900,"start":464,"enrollment":901,"conditions":924,"interventions":925},[86],[903],[884,905,906,907],{"trials":927,"activeCount":94},[],{"intervention":906,"totalTrials":133,"cells":929},{"EARLY_PHASE1":930,"PHASE1":932,"PHASE2":934,"PHASE3":936,"PHASE4":938,"NA":944},{"trials":931,"activeCount":94},[],{"trials":933,"activeCount":94},[],{"trials":935,"activeCount":94},[],{"trials":937,"activeCount":94},[],{"trials":939,"activeCount":94},[940],{"nctId":897,"briefTitle":898,"status":104,"phases":941,"primaryCompletion":900,"completion":900,"start":464,"enrollment":901,"conditions":942,"interventions":943},[86],[903],[884,905,906,907],{"trials":945,"activeCount":94},[],{"intervention":907,"totalTrials":133,"cells":947},{"EARLY_PHASE1":948,"PHASE1":950,"PHASE2":952,"PHASE3":954,"PHASE4":956,"NA":962},{"trials":949,"activeCount":94},[],{"trials":951,"activeCount":94},[],{"trials":953,"activeCount":94},[],{"trials":955,"activeCount":94},[],{"trials":957,"activeCount":94},[958],{"nctId":897,"briefTitle":898,"status":104,"phases":959,"primaryCompletion":900,"completion":900,"start":464,"enrollment":901,"conditions":960,"interventions":961},[86],[903],[884,905,906,907],{"trials":963,"activeCount":94},[],{"intervention":965,"totalTrials":133,"cells":966},"Oxytocin",{"EARLY_PHASE1":967,"PHASE1":969,"PHASE2":971,"PHASE3":973,"PHASE4":975,"NA":987},{"trials":968,"activeCount":94},[],{"trials":970,"activeCount":94},[],{"trials":972,"activeCount":94},[],{"trials":974,"activeCount":94},[],{"trials":976,"activeCount":94},[977],{"nctId":978,"briefTitle":979,"status":814,"phases":980,"primaryCompletion":981,"completion":981,"start":982,"enrollment":94,"conditions":983,"interventions":986},"NCT01252342","Does Intramyometrial Oxytocin Improve Outcome in Elective Cesarean Delivery?",[86],"2012-04","2011-08",[984,985],"Postpartum Hemorrhage","Uterine Atony",[965,112],{"trials":988,"activeCount":94},[],{"intervention":533,"totalTrials":133,"cells":990},{"EARLY_PHASE1":991,"PHASE1":993,"PHASE2":995,"PHASE3":997,"PHASE4":999,"NA":1005},{"trials":992,"activeCount":94},[],{"trials":994,"activeCount":94},[],{"trials":996,"activeCount":94},[],{"trials":998,"activeCount":94},[],{"trials":1000,"activeCount":94},[1001],{"nctId":523,"briefTitle":524,"status":525,"phases":1002,"primaryCompletion":527,"completion":527,"start":528,"enrollment":529,"conditions":1003,"interventions":1004},[86],[46,29,531],[533,132,429],{"trials":1006,"activeCount":94},[],{"intervention":394,"totalTrials":133,"cells":1008},{"EARLY_PHASE1":1009,"PHASE1":1011,"PHASE2":1013,"PHASE3":1015,"PHASE4":1017,"NA":1023},{"trials":1010,"activeCount":94},[],{"trials":1012,"activeCount":94},[],{"trials":1014,"activeCount":94},[],{"trials":1016,"activeCount":94},[],{"trials":1018,"activeCount":94},[1019],{"nctId":383,"briefTitle":384,"status":104,"phases":1020,"primaryCompletion":386,"completion":387,"start":388,"enrollment":389,"conditions":1021,"interventions":1022},[86],[29,391,392,393,394],[394,357],{"trials":1024,"activeCount":94},[],{"intervention":1026,"totalTrials":133,"cells":1027},"Indomethacin 50 MG",{"EARLY_PHASE1":1028,"PHASE1":1030,"PHASE2":1032,"PHASE3":1034,"PHASE4":1036,"NA":1048},{"trials":1029,"activeCount":94},[],{"trials":1031,"activeCount":94},[],{"trials":1033,"activeCount":94},[],{"trials":1035,"activeCount":94},[],{"trials":1037,"activeCount":94},[1038],{"nctId":1039,"briefTitle":1040,"status":525,"phases":1041,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":720,"conditions":1045,"interventions":1047},"NCT06433453","Three Dimensional Ultrasonographic Detection of Human Ovulation",[86],"2024-12-31","2025-03-31","2024-04-22",[1046],"Ovulation Disorder",[1026],{"trials":1049,"activeCount":94},[],{"intervention":1051,"totalTrials":133,"cells":1052},"De-prescribe beta blocker therapy",{"EARLY_PHASE1":1053,"PHASE1":1055,"PHASE2":1057,"PHASE3":1059,"PHASE4":1061,"NA":1076},{"trials":1054,"activeCount":94},[],{"trials":1056,"activeCount":94},[],{"trials":1058,"activeCount":94},[],{"trials":1060,"activeCount":94},[],{"trials":1062,"activeCount":94},[1063],{"nctId":1064,"briefTitle":1065,"status":525,"phases":1066,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":181,"conditions":1070,"interventions":1075},"NCT04788186","Beta Blocker De-prescription Following Coronary Artery Bypass Graft Surgery (BEEFBURGER Trial).",[86],"2024-08-31","2025-08-31","2021-08-23",[26,1071,1072,1073,1074],"Acute Myocardial Infarction","Coronary Artery Stenosis","ST Elevation Myocardial Infarction","Non-ST Elevation Myocardial Infarction (NSTEMI)",[1051],{"trials":1077,"activeCount":94},[],{"intervention":1079,"totalTrials":133,"cells":1080},"Once Daily Tacrolimus",{"EARLY_PHASE1":1081,"PHASE1":1083,"PHASE2":1085,"PHASE3":1087,"PHASE4":1089,"NA":1101},{"trials":1082,"activeCount":94},[],{"trials":1084,"activeCount":94},[],{"trials":1086,"activeCount":94},[],{"trials":1088,"activeCount":94},[],{"trials":1090,"activeCount":94},[1091],{"nctId":1092,"briefTitle":1093,"status":104,"phases":1094,"primaryCompletion":387,"completion":387,"start":1095,"enrollment":242,"conditions":1096,"interventions":1099},"NCT01702207","Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk",[86],"2012-10",[1097,1098,822],"Immunosuppression","Cardiovascular Diseases",[1079,1100],"Twice Daily Tacrolimus",{"trials":1102,"activeCount":94},[],{"intervention":1100,"totalTrials":133,"cells":1104},{"EARLY_PHASE1":1105,"PHASE1":1107,"PHASE2":1109,"PHASE3":1111,"PHASE4":1113,"NA":1119},{"trials":1106,"activeCount":94},[],{"trials":1108,"activeCount":94},[],{"trials":1110,"activeCount":94},[],{"trials":1112,"activeCount":94},[],{"trials":1114,"activeCount":94},[1115],{"nctId":1092,"briefTitle":1093,"status":104,"phases":1116,"primaryCompletion":387,"completion":387,"start":1095,"enrollment":242,"conditions":1117,"interventions":1118},[86],[1097,1098,822],[1079,1100],{"trials":1120,"activeCount":94},[],{"intervention":1122,"totalTrials":133,"cells":1123},"[F-18]-Fludeoxyglucose",{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1130,"PHASE4":1132,"NA":1144},{"trials":1125,"activeCount":94},[],{"trials":1127,"activeCount":94},[],{"trials":1129,"activeCount":94},[],{"trials":1131,"activeCount":94},[],{"trials":1133,"activeCount":94},[1134],{"nctId":1135,"briefTitle":1136,"status":104,"phases":1137,"primaryCompletion":500,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1143},"NCT02811185","Registry Type Study to Monitor for Adverse Drug Reactions to Fedoruk Manufactured [F-18]-Fludeoxyglucose",[86],"2017-01-30","2016-06",1012,[1142],"Positron-Emission Tomography and Cone-Beam Computed Tomography",[1122],{"trials":1145,"activeCount":94},[],{"intervention":1147,"totalTrials":133,"cells":1148},"Ipratropium Metered Dose Inhaler",{"EARLY_PHASE1":1149,"PHASE1":1151,"PHASE2":1153,"PHASE3":1155,"PHASE4":1157,"NA":1167},{"trials":1150,"activeCount":94},[],{"trials":1152,"activeCount":94},[],{"trials":1154,"activeCount":94},[],{"trials":1156,"activeCount":94},[],{"trials":1158,"activeCount":94},[1159],{"nctId":1160,"briefTitle":1161,"status":104,"phases":1162,"primaryCompletion":1163,"completion":1163,"start":1164,"enrollment":201,"conditions":1165,"interventions":1166},"NCT04167280","Regular Use Effect of Inhaled Ipratropium Bromide on Airway Responsiveness to Methacholine in Well-controlled Asthma",[86],"2020-03-13","2019-11-05",[15],[1147],{"trials":1168,"activeCount":94},[],{"intervention":507,"totalTrials":133,"cells":1170},{"EARLY_PHASE1":1171,"PHASE1":1173,"PHASE2":1175,"PHASE3":1177,"PHASE4":1179,"NA":1185},{"trials":1172,"activeCount":94},[],{"trials":1174,"activeCount":94},[],{"trials":1176,"activeCount":94},[],{"trials":1178,"activeCount":94},[],{"trials":1180,"activeCount":94},[1181],{"nctId":497,"briefTitle":498,"status":104,"phases":1182,"primaryCompletion":500,"completion":501,"start":502,"enrollment":503,"conditions":1183,"interventions":1184},[86],[15],[506,507],{"trials":1186,"activeCount":94},[],{"intervention":404,"totalTrials":133,"cells":1188},{"EARLY_PHASE1":1189,"PHASE1":1191,"PHASE2":1193,"PHASE3":1195,"PHASE4":1197,"NA":1203},{"trials":1190,"activeCount":94},[],{"trials":1192,"activeCount":94},[],{"trials":1194,"activeCount":94},[],{"trials":1196,"activeCount":94},[],{"trials":1198,"activeCount":94},[1199],{"nctId":397,"briefTitle":398,"status":104,"phases":1200,"primaryCompletion":400,"completion":400,"start":401,"enrollment":9,"conditions":1201,"interventions":1202},[86],[15],[404,405,357],{"trials":1204,"activeCount":94},[],{"intervention":1206,"totalTrials":133,"cells":1207},"Tiotropium Bromide",{"EARLY_PHASE1":1208,"PHASE1":1210,"PHASE2":1212,"PHASE3":1214,"PHASE4":1216,"NA":1226},{"trials":1209,"activeCount":94},[],{"trials":1211,"activeCount":94},[],{"trials":1213,"activeCount":94},[],{"trials":1215,"activeCount":94},[],{"trials":1217,"activeCount":94},[1218],{"nctId":1219,"briefTitle":1220,"status":104,"phases":1221,"primaryCompletion":1222,"completion":1222,"start":1223,"enrollment":201,"conditions":1224,"interventions":1225},"NCT05113615","Regular Use Tiotropium and Tolerance to Bronchoprotection in Mild Asthma",[86],"2022-05-06","2021-12-13",[15],[1206],{"trials":1227,"activeCount":94},[],{"intervention":1229,"totalTrials":133,"cells":1230},"ipratropium bromide",{"EARLY_PHASE1":1231,"PHASE1":1233,"PHASE2":1235,"PHASE3":1237,"PHASE4":1239,"NA":1249},{"trials":1232,"activeCount":94},[],{"trials":1234,"activeCount":94},[],{"trials":1236,"activeCount":94},[],{"trials":1238,"activeCount":94},[],{"trials":1240,"activeCount":94},[1241],{"nctId":1242,"briefTitle":1243,"status":104,"phases":1244,"primaryCompletion":1245,"completion":1245,"start":1246,"enrollment":201,"conditions":1247,"interventions":1248},"NCT00605410","Duration of Protective Effect From Inhaled Ipratropium Bromide on Methacholine Airway Hyperresponsiveness",[86],"2008-04","2008-01",[15],[1229],{"trials":1250,"activeCount":94},[],{"intervention":1252,"totalTrials":133,"cells":1253},"Metformin",{"EARLY_PHASE1":1254,"PHASE1":1256,"PHASE2":1258,"PHASE3":1260,"PHASE4":1262,"NA":1277},{"trials":1255,"activeCount":94},[],{"trials":1257,"activeCount":94},[],{"trials":1259,"activeCount":94},[],{"trials":1261,"activeCount":94},[],{"trials":1263,"activeCount":94},[1264],{"nctId":1265,"briefTitle":1266,"status":525,"phases":1267,"primaryCompletion":1268,"completion":1268,"start":1269,"enrollment":1270,"conditions":1271,"interventions":1276},"NCT03980990","Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial",[86],"2020-06-17","2019-06-17",500,[1272,1273,1274,1275],"Acute Coronary Syndrome","Unstable Angina","Diabetes Mellitus","Metformin Adverse Reaction",[1252],{"trials":1278,"activeCount":94},[],{"intervention":1280,"totalTrials":133,"cells":1281},"0.75 levonorgestrel",{"EARLY_PHASE1":1282,"PHASE1":1284,"PHASE2":1286,"PHASE3":1288,"PHASE4":1290,"NA":1302},{"trials":1283,"activeCount":94},[],{"trials":1285,"activeCount":94},[],{"trials":1287,"activeCount":94},[],{"trials":1289,"activeCount":94},[],{"trials":1291,"activeCount":94},[1292],{"nctId":1293,"briefTitle":1294,"status":104,"phases":1295,"completion":1296,"start":1297,"enrollment":439,"conditions":1298,"interventions":1300},"NCT00204451","Human Ovarian Follicular Dynamics and Emergency Contraception",[86],"2006-06","2005-07",[1299],"Contraception",[1280,1301],"50 mg ethinyl estradiol\u002F0.5 mg levonorgestrel",{"trials":1303,"activeCount":94},[],{"intervention":1301,"totalTrials":133,"cells":1305},{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1312,"PHASE4":1314,"NA":1320},{"trials":1307,"activeCount":94},[],{"trials":1309,"activeCount":94},[],{"trials":1311,"activeCount":94},[],{"trials":1313,"activeCount":94},[],{"trials":1315,"activeCount":94},[1316],{"nctId":1293,"briefTitle":1294,"status":104,"phases":1317,"completion":1296,"start":1297,"enrollment":439,"conditions":1318,"interventions":1319},[86],[1299],[1280,1301],{"trials":1321,"activeCount":94},[],{"intervention":1323,"totalTrials":133,"cells":1324},"Naproxen",{"EARLY_PHASE1":1325,"PHASE1":1327,"PHASE2":1329,"PHASE3":1331,"PHASE4":1333,"NA":1345},{"trials":1326,"activeCount":94},[],{"trials":1328,"activeCount":94},[],{"trials":1330,"activeCount":94},[],{"trials":1332,"activeCount":94},[],{"trials":1334,"activeCount":94},[1335],{"nctId":1336,"briefTitle":1337,"status":104,"phases":1338,"completion":1339,"start":1340,"enrollment":1341,"conditions":1342,"interventions":1344},"NCT00222976","Oral vs Rectal Admin of Naproxen for Post-Vag Perineal Pain Control",[86],"2007-05","2006-09",60,[1343],"Post-Vaginal Delivery Perineal Pain",[1323],{"trials":1346,"activeCount":94},[],{"intervention":1348,"totalTrials":137,"cells":1349},"normal saline",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1372,"NA":1374},{"trials":1351,"activeCount":94},[],{"trials":1353,"activeCount":94},[],{"trials":1355,"activeCount":94},[],{"trials":1357,"activeCount":94},[1358,1368],{"nctId":1359,"briefTitle":1360,"status":104,"phases":1361,"primaryCompletion":981,"completion":1362,"start":1363,"enrollment":1364,"conditions":1365,"interventions":1366},"NCT01519245","Topical Application of Tranexamic Acid to Reduce Post-operative Bleeding in Coronary Artery Bypass Surgery",[85],"2012-06","2011-12",44,[26],[1367,1348],"Tranexamic Acid",{"nctId":420,"briefTitle":421,"status":104,"phases":1369,"primaryCompletion":153,"completion":153,"start":107,"enrollment":423,"conditions":1370,"interventions":1371},[85],[425],[409,427,428,429,430],{"trials":1373,"activeCount":94},[],{"trials":1375,"activeCount":94},[],{"intervention":1377,"totalTrials":137,"cells":1378},"Acetaminophen, gabapentin",{"EARLY_PHASE1":1379,"PHASE1":1381,"PHASE2":1383,"PHASE3":1385,"PHASE4":1436,"NA":1438},{"trials":1380,"activeCount":94},[],{"trials":1382,"activeCount":94},[],{"trials":1384,"activeCount":94},[],{"trials":1386,"activeCount":94},[1387,1416],{"nctId":1388,"briefTitle":1389,"status":104,"phases":1390,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":529,"conditions":1394,"interventions":1409},"NCT02987985","Efficacy of Opioid-free Anesthesia in Reducing Postoperative Respiratory Depression in Children Undergoing Tonsillectomy",[85],"2019-09-20","2020-12-20","2017-10-15",[531,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,409,46,1406,1407,1408],"General Anesthesia","Analgesics, Opioid","Postoperative Complications","Pathologic Processes","Physiologic Effects of Drugs","Narcotics","Analgesics","Sleep Disordered Breathing","Obstructive Sleep Apnea of Child","Tonsillectomy","Respiratory Depression","Lidocaine","Gabapentin","Pulse Oximetry",[1377,1410,1411,1412,1413,1414,1415],"Acetaminophen","Ketamine , Lidocaine , Dexmedetomidine","Fentanyl, Dexmedetomidine","Dexamethasone , Ondansetron","Sevoflurane","Sevoflurane, Fentanyl",{"nctId":1417,"briefTitle":1418,"status":525,"phases":1419,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1341,"conditions":1423,"interventions":1429},"NCT04144933","Effect of Multimodal Opioid-free Anesthesia on Return of Bowel Function in Laparoscopic Colorectal Surgery",[85],"2024-07-30","2024-08-01","2021-05-15",[531,1395,1396,1424,1425,1426,1427,1428,409,1406,46],"Opioid Free Anesthesia","Postoperative Ileus","Colorectal Surgery","Laparoscopic Surgery","Analgesia",[1430,1430,1431,1432,1433,1434,1435],"Acetaminophen, Gabapentin","Lidocaine 1% Injectable Solution, Dexmedetomidine, Ketamine","Dexamethasone, Ondansetron","Sevoflurane, Lidocaine 2% Injectable Solution, Ketamine, Dexmedetomidine, Magnesium Sulfate","Lidocaine 1% Injectable Solution, Sufentanil","Sevoflurane, Sufentanil",{"trials":1437,"activeCount":94},[],{"trials":1439,"activeCount":94},[],{"intervention":1367,"totalTrials":133,"cells":1441},{"EARLY_PHASE1":1442,"PHASE1":1444,"PHASE2":1446,"PHASE3":1448,"PHASE4":1454,"NA":1456},{"trials":1443,"activeCount":94},[],{"trials":1445,"activeCount":94},[],{"trials":1447,"activeCount":94},[],{"trials":1449,"activeCount":94},[1450],{"nctId":1359,"briefTitle":1360,"status":104,"phases":1451,"primaryCompletion":981,"completion":1362,"start":1363,"enrollment":1364,"conditions":1452,"interventions":1453},[85],[26],[1367,1348],{"trials":1455,"activeCount":94},[],{"trials":1457,"activeCount":94},[],{"intervention":1459,"totalTrials":133,"cells":1460},"68Ga-PSMA PET\u002FCT",{"EARLY_PHASE1":1461,"PHASE1":1463,"PHASE2":1465,"PHASE3":1467,"PHASE4":1480,"NA":1482},{"trials":1462,"activeCount":94},[],{"trials":1464,"activeCount":94},[],{"trials":1466,"activeCount":94},[],{"trials":1468,"activeCount":94},[1469],{"nctId":1470,"briefTitle":1471,"status":1472,"phases":1473,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":1270,"conditions":1477,"interventions":1479},"NCT04684628","68Ga-PSMA PET\u002FCT in Prostate Cancer","SUSPENDED",[85],"2025-01","2025-12","2020-12-09",[1478],"Prostate Cancer",[1459],{"trials":1481,"activeCount":94},[],{"trials":1483,"activeCount":94},[],{"intervention":1485,"totalTrials":133,"cells":1486},"Diazoxide",{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1491,"PHASE3":1493,"PHASE4":1510,"NA":1512},{"trials":1488,"activeCount":94},[],{"trials":1490,"activeCount":94},[],{"trials":1492,"activeCount":94},[],{"trials":1494,"activeCount":94},[1495],{"nctId":1496,"briefTitle":1497,"status":525,"phases":1498,"primaryCompletion":1499,"completion":1499,"start":1500,"enrollment":1501,"conditions":1502,"interventions":1508},"NCT00994149","Diazoxide In the Management Of Hypoglycemic Neonates",[84,85],"2011-10","2009-10",100,[1503,1504,1505,1506,1507],"Infant, Newborn, Diseases","Pregnancy in Diabetics","Infant, Diabetic Mother","Hypoglycemia","Infant, Large for Gestational Age",[1485,1509],"Ora-plus",{"trials":1511,"activeCount":94},[],{"trials":1513,"activeCount":94},[],{"intervention":1509,"totalTrials":133,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1528,"NA":1530},{"trials":1517,"activeCount":94},[],{"trials":1519,"activeCount":94},[],{"trials":1521,"activeCount":94},[],{"trials":1523,"activeCount":94},[1524],{"nctId":1496,"briefTitle":1497,"status":525,"phases":1525,"primaryCompletion":1499,"completion":1499,"start":1500,"enrollment":1501,"conditions":1526,"interventions":1527},[84,85],[1503,1504,1505,1506,1507],[1485,1509],{"trials":1529,"activeCount":94},[],{"trials":1531,"activeCount":94},[],{"intervention":427,"totalTrials":133,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":94},[],{"trials":1537,"activeCount":94},[],{"trials":1539,"activeCount":94},[],{"trials":1541,"activeCount":94},[1542],{"nctId":420,"briefTitle":421,"status":104,"phases":1543,"primaryCompletion":153,"completion":153,"start":107,"enrollment":423,"conditions":1544,"interventions":1545},[85],[425],[409,427,428,429,430],{"trials":1547,"activeCount":94},[],{"trials":1549,"activeCount":94},[],{"intervention":430,"totalTrials":133,"cells":1551},{"EARLY_PHASE1":1552,"PHASE1":1554,"PHASE2":1556,"PHASE3":1558,"PHASE4":1564,"NA":1566},{"trials":1553,"activeCount":94},[],{"trials":1555,"activeCount":94},[],{"trials":1557,"activeCount":94},[],{"trials":1559,"activeCount":94},[1560],{"nctId":420,"briefTitle":421,"status":104,"phases":1561,"primaryCompletion":153,"completion":153,"start":107,"enrollment":423,"conditions":1562,"interventions":1563},[85],[425],[409,427,428,429,430],{"trials":1565,"activeCount":94},[],{"trials":1567,"activeCount":94},[],{"intervention":1410,"totalTrials":133,"cells":1569},{"EARLY_PHASE1":1570,"PHASE1":1572,"PHASE2":1574,"PHASE3":1576,"PHASE4":1582,"NA":1584},{"trials":1571,"activeCount":94},[],{"trials":1573,"activeCount":94},[],{"trials":1575,"activeCount":94},[],{"trials":1577,"activeCount":94},[1578],{"nctId":1388,"briefTitle":1389,"status":104,"phases":1579,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":529,"conditions":1580,"interventions":1581},[85],[531,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,409,46,1406,1407,1408],[1377,1410,1411,1412,1413,1414,1415],{"trials":1583,"activeCount":94},[],{"trials":1585,"activeCount":94},[],{"intervention":1411,"totalTrials":133,"cells":1587},{"EARLY_PHASE1":1588,"PHASE1":1590,"PHASE2":1592,"PHASE3":1594,"PHASE4":1600,"NA":1602},{"trials":1589,"activeCount":94},[],{"trials":1591,"activeCount":94},[],{"trials":1593,"activeCount":94},[],{"trials":1595,"activeCount":94},[1596],{"nctId":1388,"briefTitle":1389,"status":104,"phases":1597,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":529,"conditions":1598,"interventions":1599},[85],[531,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,409,46,1406,1407,1408],[1377,1410,1411,1412,1413,1414,1415],{"trials":1601,"activeCount":94},[],{"trials":1603,"activeCount":94},[],{"intervention":1412,"totalTrials":133,"cells":1605},{"EARLY_PHASE1":1606,"PHASE1":1608,"PHASE2":1610,"PHASE3":1612,"PHASE4":1618,"NA":1620},{"trials":1607,"activeCount":94},[],{"trials":1609,"activeCount":94},[],{"trials":1611,"activeCount":94},[],{"trials":1613,"activeCount":94},[1614],{"nctId":1388,"briefTitle":1389,"status":104,"phases":1615,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":529,"conditions":1616,"interventions":1617},[85],[531,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,409,46,1406,1407,1408],[1377,1410,1411,1412,1413,1414,1415],{"trials":1619,"activeCount":94},[],{"trials":1621,"activeCount":94},[],{"intervention":1413,"totalTrials":133,"cells":1623},{"EARLY_PHASE1":1624,"PHASE1":1626,"PHASE2":1628,"PHASE3":1630,"PHASE4":1636,"NA":1638},{"trials":1625,"activeCount":94},[],{"trials":1627,"activeCount":94},[],{"trials":1629,"activeCount":94},[],{"trials":1631,"activeCount":94},[1632],{"nctId":1388,"briefTitle":1389,"status":104,"phases":1633,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":529,"conditions":1634,"interventions":1635},[85],[531,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,409,46,1406,1407,1408],[1377,1410,1411,1412,1413,1414,1415],{"trials":1637,"activeCount":94},[],{"trials":1639,"activeCount":94},[],{"intervention":1415,"totalTrials":133,"cells":1641},{"EARLY_PHASE1":1642,"PHASE1":1644,"PHASE2":1646,"PHASE3":1648,"PHASE4":1654,"NA":1656},{"trials":1643,"activeCount":94},[],{"trials":1645,"activeCount":94},[],{"trials":1647,"activeCount":94},[],{"trials":1649,"activeCount":94},[1650],{"nctId":1388,"briefTitle":1389,"status":104,"phases":1651,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":529,"conditions":1652,"interventions":1653},[85],[531,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,409,46,1406,1407,1408],[1377,1410,1411,1412,1413,1414,1415],{"trials":1655,"activeCount":94},[],{"trials":1657,"activeCount":94},[],{"intervention":1659,"totalTrials":133,"cells":1660},"Tranexamic Acid 100 MG\u002FML",{"EARLY_PHASE1":1661,"PHASE1":1663,"PHASE2":1665,"PHASE3":1667,"PHASE4":1682,"NA":1684},{"trials":1662,"activeCount":94},[],{"trials":1664,"activeCount":94},[],{"trials":1666,"activeCount":94},[],{"trials":1668,"activeCount":94},[1669],{"nctId":1670,"briefTitle":1671,"status":525,"phases":1672,"primaryCompletion":1673,"completion":1674,"start":1675,"enrollment":529,"conditions":1676,"interventions":1681},"NCT04865380","Does Tranexamic Acid Improve Visualization During Arthroscopic Rotator Cuff Repair",[85],"2021-12","2022-04","2021-01-13",[1677,1678,1679,1680],"Rotator Cuff Tears","Rotator Cuff Injuries","Subacromial Impingement","Subacromial Impingement Syndrome",[1659],{"trials":1683,"activeCount":94},[],{"trials":1685,"activeCount":94},[],{"intervention":1431,"totalTrials":133,"cells":1687},{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1694,"PHASE4":1700,"NA":1702},{"trials":1689,"activeCount":94},[],{"trials":1691,"activeCount":94},[],{"trials":1693,"activeCount":94},[],{"trials":1695,"activeCount":94},[1696],{"nctId":1417,"briefTitle":1418,"status":525,"phases":1697,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1341,"conditions":1698,"interventions":1699},[85],[531,1395,1396,1424,1425,1426,1427,1428,409,1406,46],[1430,1430,1431,1432,1433,1434,1435],{"trials":1701,"activeCount":94},[],{"trials":1703,"activeCount":94},[],{"intervention":1432,"totalTrials":133,"cells":1705},{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1712,"PHASE4":1718,"NA":1720},{"trials":1707,"activeCount":94},[],{"trials":1709,"activeCount":94},[],{"trials":1711,"activeCount":94},[],{"trials":1713,"activeCount":94},[1714],{"nctId":1417,"briefTitle":1418,"status":525,"phases":1715,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1341,"conditions":1716,"interventions":1717},[85],[531,1395,1396,1424,1425,1426,1427,1428,409,1406,46],[1430,1430,1431,1432,1433,1434,1435],{"trials":1719,"activeCount":94},[],{"trials":1721,"activeCount":94},[],{"intervention":1433,"totalTrials":133,"cells":1723},{"EARLY_PHASE1":1724,"PHASE1":1726,"PHASE2":1728,"PHASE3":1730,"PHASE4":1736,"NA":1738},{"trials":1725,"activeCount":94},[],{"trials":1727,"activeCount":94},[],{"trials":1729,"activeCount":94},[],{"trials":1731,"activeCount":94},[1732],{"nctId":1417,"briefTitle":1418,"status":525,"phases":1733,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1341,"conditions":1734,"interventions":1735},[85],[531,1395,1396,1424,1425,1426,1427,1428,409,1406,46],[1430,1430,1431,1432,1433,1434,1435],{"trials":1737,"activeCount":94},[],{"trials":1739,"activeCount":94},[],{"intervention":1434,"totalTrials":133,"cells":1741},{"EARLY_PHASE1":1742,"PHASE1":1744,"PHASE2":1746,"PHASE3":1748,"PHASE4":1754,"NA":1756},{"trials":1743,"activeCount":94},[],{"trials":1745,"activeCount":94},[],{"trials":1747,"activeCount":94},[],{"trials":1749,"activeCount":94},[1750],{"nctId":1417,"briefTitle":1418,"status":525,"phases":1751,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1341,"conditions":1752,"interventions":1753},[85],[531,1395,1396,1424,1425,1426,1427,1428,409,1406,46],[1430,1430,1431,1432,1433,1434,1435],{"trials":1755,"activeCount":94},[],{"trials":1757,"activeCount":94},[],{"intervention":1435,"totalTrials":133,"cells":1759},{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1766,"PHASE4":1772,"NA":1774},{"trials":1761,"activeCount":94},[],{"trials":1763,"activeCount":94},[],{"trials":1765,"activeCount":94},[],{"trials":1767,"activeCount":94},[1768],{"nctId":1417,"briefTitle":1418,"status":525,"phases":1769,"primaryCompletion":1420,"completion":1421,"start":1422,"enrollment":1341,"conditions":1770,"interventions":1771},[85],[531,1395,1396,1424,1425,1426,1427,1428,409,1406,46],[1430,1430,1431,1432,1433,1434,1435],{"trials":1773,"activeCount":94},[],{"trials":1775,"activeCount":94},[],{"intervention":1777,"totalTrials":133,"cells":1778},"Misoprostol",{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1798,"NA":1800},{"trials":1780,"activeCount":94},[],{"trials":1782,"activeCount":94},[],{"trials":1784,"activeCount":94},[],{"trials":1786,"activeCount":94},[1787],{"nctId":1788,"briefTitle":1789,"status":814,"phases":1790,"primaryCompletion":1791,"completion":1791,"start":1792,"enrollment":94,"conditions":1793,"interventions":1797},"NCT00953641","Vaginal Misoprostol for Cervical Ripening Prior to Endometrial Biopsy",[85],"2012-09","2011-09",[1794,1795,1796],"Menorrhagia","Endometrial Biopsy","Cervical Ripening",[1777],{"trials":1799,"activeCount":94},[],{"trials":1801,"activeCount":94},[],{"intervention":1803,"totalTrials":30,"cells":1804},"Saline Placebo",{"EARLY_PHASE1":1805,"PHASE1":1807,"PHASE2":1849,"PHASE3":1859,"PHASE4":1861,"NA":1863},{"trials":1806,"activeCount":94},[],{"trials":1808,"activeCount":94},[1809,1820,1829,1839],{"nctId":1810,"briefTitle":1811,"status":814,"phases":1812,"primaryCompletion":1813,"completion":1814,"start":1815,"enrollment":94,"conditions":1816,"interventions":1818},"NCT05155982","A Clinical Trial of COVAC-1, a COVID-19 Vaccine, in Generally Healthy Adults",[83],"2023-06","2023-10","2022-06",[1817],"Severe Acute Respiratory Syndrome Coronavirus 2",[1819,1803],"COVAC-1",{"nctId":1821,"briefTitle":1822,"status":104,"phases":1823,"primaryCompletion":1824,"completion":1824,"start":1825,"enrollment":108,"conditions":1826,"interventions":1827},"NCT04702178","A Clinical Trial of COVAC-2 in Healthy Adults",[83],"2022-11-02","2021-02-10",[1817],[1828,1803],"COVAC-2",{"nctId":1830,"briefTitle":1831,"status":104,"phases":1832,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":1341,"conditions":1835,"interventions":1838},"NCT05226702","Clinical Trial to Study the COVAC-2 Booster Dose (for COVID-19) in Generally Healthy Adults.",[83],"2023-11-13","2022-07-22",[1836,1837],"Double Vaccinated for COVID-19 (For Phase 1 of the Study)","Acute Respiratory Syndrome Coronavirus 2 (For Phase 2 Exploratory Group)",[1828,1803],{"nctId":1840,"briefTitle":1841,"status":104,"phases":1842,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":1846,"interventions":1848},"NCT05693272","A Clinical Trial to Study the COVAC-1 Booster Dose in Generally Healthy Adults",[83],"2024-06-04","2023-01-31",47,[1847],"Severe Acute Respiratory Syndrome Coronavirus 2 Infection",[1819,1803],{"trials":1850,"activeCount":94},[1851],{"nctId":1852,"briefTitle":1853,"status":104,"phases":1854,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":389,"conditions":1857,"interventions":1858},"NCT05209009","A Clinical Trial of COVAC-2 in Adults",[84],"2024-03-01","2022-08-24",[1817],[1828,1803],{"trials":1860,"activeCount":94},[],{"trials":1862,"activeCount":94},[],{"trials":1864,"activeCount":94},[],{"intervention":1828,"totalTrials":90,"cells":1866},{"EARLY_PHASE1":1867,"PHASE1":1869,"PHASE2":1879,"PHASE3":1885,"PHASE4":1887,"NA":1889},{"trials":1868,"activeCount":94},[],{"trials":1870,"activeCount":94},[1871,1875],{"nctId":1821,"briefTitle":1822,"status":104,"phases":1872,"primaryCompletion":1824,"completion":1824,"start":1825,"enrollment":108,"conditions":1873,"interventions":1874},[83],[1817],[1828,1803],{"nctId":1830,"briefTitle":1831,"status":104,"phases":1876,"primaryCompletion":1833,"completion":1833,"start":1834,"enrollment":1341,"conditions":1877,"interventions":1878},[83],[1836,1837],[1828,1803],{"trials":1880,"activeCount":94},[1881],{"nctId":1852,"briefTitle":1853,"status":104,"phases":1882,"primaryCompletion":1855,"completion":1855,"start":1856,"enrollment":389,"conditions":1883,"interventions":1884},[84],[1817],[1828,1803],{"trials":1886,"activeCount":94},[],{"trials":1888,"activeCount":94},[],{"trials":1890,"activeCount":94},[],{"intervention":1892,"totalTrials":133,"cells":1893},"Weekly Taxotere with weekly carboplatin",{"EARLY_PHASE1":1894,"PHASE1":1896,"PHASE2":1898,"PHASE3":1911,"PHASE4":1913,"NA":1915},{"trials":1895,"activeCount":94},[],{"trials":1897,"activeCount":94},[],{"trials":1899,"activeCount":94},[1900],{"nctId":1901,"briefTitle":1902,"status":1903,"phases":1904,"completion":1905,"start":1906,"enrollment":1907,"conditions":1908,"interventions":1910},"NCT00247988","Weekly Carboplatin and Taxotere in Platinum Sensitive Relapsed Ovarian or Tubal or Primary Peritoneal Cancers","TERMINATED",[84],"2007-04","2003-10",38,[1909],"Platinum Sensitive Relapsed Ovarian Cancer",[1892],{"trials":1912,"activeCount":94},[],{"trials":1914,"activeCount":94},[],{"trials":1916,"activeCount":94},[],{"intervention":1918,"totalTrials":133,"cells":1919},"Dexamethasone",{"EARLY_PHASE1":1920,"PHASE1":1922,"PHASE2":1924,"PHASE3":1940,"PHASE4":1942,"NA":1944},{"trials":1921,"activeCount":94},[],{"trials":1923,"activeCount":94},[],{"trials":1925,"activeCount":94},[1926],{"nctId":1927,"briefTitle":1928,"status":525,"phases":1929,"primaryCompletion":1930,"completion":1067,"start":1931,"enrollment":1341,"conditions":1932,"interventions":1939},"NCT05432934","Transversus Abdominis Plane Blocks With and Without Dexamethasone",[83,84],"2024-03-31","2022-09-01",[1933,1934,1428,1935,1936,309,1937,1938],"Colorectal Disorders","Regional Anesthesia Morbidity","Local Anesthetic Complication","Pain, Postoperative","Crohn Disease","Diverticular Diseases",[1918],{"trials":1941,"activeCount":94},[],{"trials":1943,"activeCount":94},[],{"trials":1945,"activeCount":94},[],{"intervention":1947,"totalTrials":133,"cells":1948},"carboplatin\u002Fgemcitabine, carboplatin\u002Ftaxol",{"EARLY_PHASE1":1949,"PHASE1":1951,"PHASE2":1953,"PHASE3":1963,"PHASE4":1965,"NA":1967},{"trials":1950,"activeCount":94},[],{"trials":1952,"activeCount":94},[],{"trials":1954,"activeCount":94},[1955],{"nctId":1956,"briefTitle":1957,"status":104,"phases":1958,"completion":1339,"start":1959,"enrollment":1501,"conditions":1960,"interventions":1962},"NCT00259675","Alternating Cycles of Carboplatin\u002FGemcitabine and Carboplatin\u002FTaxol for Advanced Stage NSCLC",[84],"2004-05",[1961],"Non Small Cell Lung Cancer",[1947],{"trials":1964,"activeCount":94},[],{"trials":1966,"activeCount":94},[],{"trials":1968,"activeCount":94},[],{"intervention":1970,"totalTrials":133,"cells":1971},"Methadone",{"EARLY_PHASE1":1972,"PHASE1":1974,"PHASE2":1976,"PHASE3":1987,"PHASE4":1989,"NA":1991},{"trials":1973,"activeCount":94},[],{"trials":1975,"activeCount":94},[],{"trials":1977,"activeCount":94},[1978],{"nctId":1979,"briefTitle":1980,"status":104,"phases":1981,"primaryCompletion":1982,"completion":387,"start":1983,"enrollment":1984,"conditions":1985,"interventions":1986},"NCT02774499","Preoperative Oral Methadone for Patients Undergoing Cardiac Surgery: Reduction of Postoperative Pain",[84],"2016-08","2016-04",21,[24],[1970],{"trials":1988,"activeCount":94},[],{"trials":1990,"activeCount":94},[],{"trials":1992,"activeCount":94},[],{"intervention":1994,"totalTrials":133,"cells":1995},"FOLFOX and FOLFIRI",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2011,"PHASE4":2013,"NA":2015},{"trials":1997,"activeCount":94},[],{"trials":1999,"activeCount":94},[],{"trials":2001,"activeCount":94},[2002],{"nctId":2003,"briefTitle":2004,"status":1903,"phases":2005,"primaryCompletion":2006,"completion":2006,"start":2007,"enrollment":242,"conditions":2008,"interventions":2010},"NCT03528876","FOLFIRI Alternate With FOLFOX in Untreated Metastatic Gastric and Esophageal Adenocarcinoma",[84],"2020-10-29","2018-09-01",[2009],"Metastatic Gastro-esophageal Adenocarcinoma",[1994],{"trials":2012,"activeCount":94},[],{"trials":2014,"activeCount":94},[],{"trials":2016,"activeCount":94},[],{"intervention":1819,"totalTrials":137,"cells":2018},{"EARLY_PHASE1":2019,"PHASE1":2021,"PHASE2":2031,"PHASE3":2033,"PHASE4":2035,"NA":2037},{"trials":2020,"activeCount":94},[],{"trials":2022,"activeCount":94},[2023,2027],{"nctId":1810,"briefTitle":1811,"status":814,"phases":2024,"primaryCompletion":1813,"completion":1814,"start":1815,"enrollment":94,"conditions":2025,"interventions":2026},[83],[1817],[1819,1803],{"nctId":1840,"briefTitle":1841,"status":104,"phases":2028,"primaryCompletion":1843,"completion":1843,"start":1844,"enrollment":1845,"conditions":2029,"interventions":2030},[83],[1847],[1819,1803],{"trials":2032,"activeCount":94},[],{"trials":2034,"activeCount":94},[],{"trials":2036,"activeCount":94},[],{"trials":2038,"activeCount":94},[],{"intervention":2040,"totalTrials":133,"cells":2041},"UPA",{"EARLY_PHASE1":2042,"PHASE1":2044,"PHASE2":2056,"PHASE3":2058,"PHASE4":2060,"NA":2062},{"trials":2043,"activeCount":94},[],{"trials":2045,"activeCount":94},[2046],{"nctId":2047,"briefTitle":2048,"status":814,"phases":2049,"primaryCompletion":2050,"completion":2051,"start":2050,"enrollment":94,"conditions":2052,"interventions":2054},"NCT03027973","Quality of Life Outcomes for Ulipristal Acetate and Tranexamic Acid in the Management of Heavy Menstrual Bleeding",[83],"2020-01","2020-01-17",[2053],"Heavy Menstrual Bleeding",[2040,2055],"TEA",{"trials":2057,"activeCount":94},[],{"trials":2059,"activeCount":94},[],{"trials":2061,"activeCount":94},[],{"trials":2063,"activeCount":94},[],{"intervention":2055,"totalTrials":133,"cells":2065},{"EARLY_PHASE1":2066,"PHASE1":2068,"PHASE2":2074,"PHASE3":2076,"PHASE4":2078,"NA":2080},{"trials":2067,"activeCount":94},[],{"trials":2069,"activeCount":94},[2070],{"nctId":2047,"briefTitle":2048,"status":814,"phases":2071,"primaryCompletion":2050,"completion":2051,"start":2050,"enrollment":94,"conditions":2072,"interventions":2073},[83],[2053],[2040,2055],{"trials":2075,"activeCount":94},[],{"trials":2077,"activeCount":94},[],{"trials":2079,"activeCount":94},[],{"trials":2081,"activeCount":94},[],{"intervention":2083,"totalTrials":133,"cells":2084},"CanniMed® 1:20",{"EARLY_PHASE1":2085,"PHASE1":2087,"PHASE2":2098,"PHASE3":2100,"PHASE4":2102,"NA":2104},{"trials":2086,"activeCount":94},[],{"trials":2088,"activeCount":94},[2089],{"nctId":2090,"briefTitle":2091,"status":525,"phases":2092,"primaryCompletion":306,"completion":2093,"start":2094,"enrollment":16,"conditions":2095,"interventions":2097},"NCT03024827","Cannabidiol in Children With Refractory Epileptic Encephalopathy",[83],"2023-12-31","2017-04-26",[2096],"Epileptic Encephalopathy",[2083],{"trials":2099,"activeCount":94},[],{"trials":2101,"activeCount":94},[],{"trials":2103,"activeCount":94},[],{"trials":2105,"activeCount":94},[],{"intervention":2107,"totalTrials":133,"cells":2108},"Estradiol Hemihydrate Transdermal System",{"EARLY_PHASE1":2109,"PHASE1":2111,"PHASE2":2122,"PHASE3":2124,"PHASE4":2126,"NA":2128},{"trials":2110,"activeCount":94},[],{"trials":2112,"activeCount":94},[2113],{"nctId":2114,"briefTitle":2115,"status":814,"phases":2116,"primaryCompletion":2117,"completion":2117,"start":2118,"enrollment":94,"conditions":2119,"interventions":2121},"NCT04021017","PRE-GAiN Bone Health Pilot Study",[83],"2022-12-13","2020-01-21",[2120],"Anorexia Nervosa",[2107],{"trials":2123,"activeCount":94},[],{"trials":2125,"activeCount":94},[],{"trials":2127,"activeCount":94},[],{"trials":2129,"activeCount":94},[],{"intervention":2131,"totalTrials":133,"cells":2132},"Epidural Fentanyl Bolus",{"EARLY_PHASE1":2133,"PHASE1":2135,"PHASE2":2152,"PHASE3":2154,"PHASE4":2156,"NA":2158},{"trials":2134,"activeCount":94},[],{"trials":2136,"activeCount":94},[2137],{"nctId":2138,"briefTitle":2139,"status":1903,"phases":2140,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":30,"conditions":2143,"interventions":2150},"NCT04011098","Improving Labour Induction Analgesia: Epidural Fentanyl Bolus at Epidural Initiation for Induction of Labour",[83],"2020-11-02","2019-07-01",[2144,2145,2146,2147,2148,2149],"Epidural","Labor Pain","Induction of Labor Affected Fetus \u002F Newborn","Obstetric Anesthesia Problems","Obstetric Pain","Opioid",[2131,2151],"Standard Epidural Group",{"trials":2153,"activeCount":94},[],{"trials":2155,"activeCount":94},[],{"trials":2157,"activeCount":94},[],{"trials":2159,"activeCount":94},[],{"intervention":2151,"totalTrials":133,"cells":2161},{"EARLY_PHASE1":2162,"PHASE1":2164,"PHASE2":2170,"PHASE3":2172,"PHASE4":2174,"NA":2176},{"trials":2163,"activeCount":94},[],{"trials":2165,"activeCount":94},[2166],{"nctId":2138,"briefTitle":2139,"status":1903,"phases":2167,"primaryCompletion":2141,"completion":2141,"start":2142,"enrollment":30,"conditions":2168,"interventions":2169},[83],[2144,2145,2146,2147,2148,2149],[2131,2151],{"trials":2171,"activeCount":94},[],{"trials":2173,"activeCount":94},[],{"trials":2175,"activeCount":94},[],{"trials":2177,"activeCount":94},[],{"intervention":582,"totalTrials":90,"cells":2179},{"EARLY_PHASE1":2180,"PHASE1":2182,"PHASE2":2184,"PHASE3":2186,"PHASE4":2192,"NA":2198},{"trials":2181,"activeCount":94},[],{"trials":2183,"activeCount":94},[],{"trials":2185,"activeCount":94},[],{"trials":2187,"activeCount":94},[2188],{"nctId":574,"briefTitle":575,"status":104,"phases":2189,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":2190,"interventions":2191},[85],[15],[563,582],{"trials":2193,"activeCount":94},[2194],{"nctId":586,"briefTitle":587,"status":104,"phases":2195,"primaryCompletion":589,"completion":589,"start":590,"enrollment":16,"conditions":2196,"interventions":2197},[86],[15],[563,582,563],{"trials":2199,"activeCount":94},[2200],{"nctId":2201,"briefTitle":2202,"status":104,"phases":2203,"primaryCompletion":2204,"completion":2204,"start":1095,"enrollment":11,"conditions":2205,"interventions":2206},"NCT01699594","Change in Airway Responsiveness After Allergen Exposure",[87],"2014-05",[696],[582,2207],"Methacholine Chloride",{"intervention":112,"totalTrials":90,"cells":2209},{"EARLY_PHASE1":2210,"PHASE1":2212,"PHASE2":2214,"PHASE3":2216,"PHASE4":2222,"NA":2228},{"trials":2211,"activeCount":94},[],{"trials":2213,"activeCount":94},[],{"trials":2215,"activeCount":94},[],{"trials":2217,"activeCount":94},[2218],{"nctId":102,"briefTitle":103,"status":104,"phases":2219,"primaryCompletion":106,"completion":106,"start":107,"enrollment":108,"conditions":2220,"interventions":2221},[84,85],[110,24],[46,112],{"trials":2223,"activeCount":94},[2224],{"nctId":978,"briefTitle":979,"status":814,"phases":2225,"primaryCompletion":981,"completion":981,"start":982,"enrollment":94,"conditions":2226,"interventions":2227},[86],[984,985],[965,112],{"trials":2229,"activeCount":94},[2230],{"nctId":2231,"briefTitle":2232,"status":104,"phases":2233,"primaryCompletion":2234,"completion":2234,"start":2235,"enrollment":2236,"conditions":2237,"interventions":2239},"NCT02108847","Ultrasound Guided Fascia Iliaca Block for Pain Control After Elective Hip Replacement Surgery",[87],"2015-04","2014-04",42,[2238,726],"Arthroplasty, Replacement, Hip",[2240,112],".2% Ropivacaine",{"intervention":2242,"totalTrials":137,"cells":2243},"Letrozole",{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2252,"NA":2264},{"trials":2245,"activeCount":94},[],{"trials":2247,"activeCount":94},[],{"trials":2249,"activeCount":94},[],{"trials":2251,"activeCount":94},[],{"trials":2253,"activeCount":94},[2254],{"nctId":2255,"briefTitle":2256,"status":104,"phases":2257,"primaryCompletion":2258,"completion":2258,"start":2259,"enrollment":2260,"conditions":2261,"interventions":2263},"NCT01046578","Aromatase Inhibitor Effects on Ovarian Function During the Follicular and Early Luteal Phase in Women",[86],"2012-02","2010-01",41,[2262],"Fertility",[2242,2242,2242,2242,2242,2242],{"trials":2265,"activeCount":94},[2266],{"nctId":2267,"briefTitle":2268,"status":104,"phases":2269,"primaryCompletion":2270,"completion":2270,"start":2271,"enrollment":2260,"conditions":2272,"interventions":2274},"NCT00565240","Mid-luteal Phase Synchronization of Ovarian Folliculogenesis in Women",[87],"2009-09","2007-11",[2273],"Ovarian Follicle",[2275,2276,2242],"Marvelon","Nuvaring",{"intervention":1414,"totalTrials":137,"cells":2278},{"EARLY_PHASE1":2279,"PHASE1":2281,"PHASE2":2283,"PHASE3":2285,"PHASE4":2291,"NA":2293},{"trials":2280,"activeCount":94},[],{"trials":2282,"activeCount":94},[],{"trials":2284,"activeCount":94},[],{"trials":2286,"activeCount":94},[2287],{"nctId":1388,"briefTitle":1389,"status":104,"phases":2288,"primaryCompletion":1391,"completion":1392,"start":1393,"enrollment":529,"conditions":2289,"interventions":2290},[85],[531,1395,1396,1397,1398,1399,1400,1401,1402,1403,1404,1405,409,46,1406,1407,1408],[1377,1410,1411,1412,1413,1414,1415],{"trials":2292,"activeCount":94},[],{"trials":2294,"activeCount":94},[2295],{"nctId":2296,"briefTitle":2297,"status":104,"phases":2298,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":2301,"conditions":2302,"interventions":2311},"NCT02639806","General Anesthesia for Endovascular Thrombectomy; A Pilot Study.",[],"2020-12","2016-01",34,[2303,2304,2305,2306,1098,2307,2308,2309,2310],"Stroke","Cerebrovascular Stroke","Brain Ischemia","Brain Diseases","Central Nervous System Diseases","Cerebrovascular Disorders","Nervous System Diseases","Vascular Diseases",[1414,1406],{"intervention":1406,"totalTrials":137,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2322,"NA":2324},{"trials":2315,"activeCount":94},[],{"trials":2317,"activeCount":94},[],{"trials":2319,"activeCount":94},[],{"trials":2321,"activeCount":94},[],{"trials":2323,"activeCount":94},[],{"trials":2325,"activeCount":94},[2326,2330],{"nctId":2296,"briefTitle":2297,"status":104,"phases":2327,"primaryCompletion":2299,"completion":2299,"start":2300,"enrollment":2301,"conditions":2328,"interventions":2329},[],[2303,2304,2305,2306,1098,2307,2308,2309,2310],[1414,1406],{"nctId":2331,"briefTitle":2332,"status":104,"phases":2333,"primaryCompletion":589,"completion":589,"start":2334,"enrollment":2335,"conditions":2336,"interventions":2337},"NCT01277835","Intravenous Lidocaine Infusion During Video-assisted Thoracic Procedures for Improved Pain Control",[87],"2010-02",48,[24],[1406],{"intervention":2207,"totalTrials":133,"cells":2339},{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2344,"PHASE3":2346,"PHASE4":2348,"NA":2350},{"trials":2341,"activeCount":94},[],{"trials":2343,"activeCount":94},[],{"trials":2345,"activeCount":94},[],{"trials":2347,"activeCount":94},[],{"trials":2349,"activeCount":94},[],{"trials":2351,"activeCount":94},[2352],{"nctId":2201,"briefTitle":2202,"status":104,"phases":2353,"primaryCompletion":2204,"completion":2204,"start":1095,"enrollment":11,"conditions":2354,"interventions":2355},[87],[696],[582,2207],{"intervention":2357,"totalTrials":133,"cells":2358},"Non-steroidal anti-inflammatory drug",{"EARLY_PHASE1":2359,"PHASE1":2361,"PHASE2":2363,"PHASE3":2365,"PHASE4":2367,"NA":2369},{"trials":2360,"activeCount":94},[],{"trials":2362,"activeCount":94},[],{"trials":2364,"activeCount":94},[],{"trials":2366,"activeCount":94},[],{"trials":2368,"activeCount":94},[],{"trials":2370,"activeCount":94},[2371],{"nctId":2372,"briefTitle":2373,"status":104,"phases":2374,"primaryCompletion":2375,"completion":2375,"start":2376,"enrollment":284,"conditions":2377,"interventions":2378},"NCT01886196","Ibuprofen Supplementation After Resistance Training and Its Effects on Bone in Older Women",[87],"2014-07","2013-04",[21,18],[2357],{"intervention":2380,"totalTrials":133,"cells":2381},"Dextrose",{"EARLY_PHASE1":2382,"PHASE1":2384,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2392},{"trials":2383,"activeCount":94},[],{"trials":2385,"activeCount":94},[],{"trials":2387,"activeCount":94},[],{"trials":2389,"activeCount":94},[],{"trials":2391,"activeCount":94},[],{"trials":2393,"activeCount":94},[2394],{"nctId":2395,"briefTitle":2396,"status":104,"phases":2397,"primaryCompletion":2398,"completion":2398,"start":438,"enrollment":2399,"conditions":2400,"interventions":2402},"NCT01912807","Postoperative Vomiting in Children - Is Dextrose an Effective Prophylactic Anti-emetic?",[87],"2014-09",300,[2401],"Postoperative Vomiting",[2380,2403],"Ondansetron",{"intervention":2403,"totalTrials":133,"cells":2405},{"EARLY_PHASE1":2406,"PHASE1":2408,"PHASE2":2410,"PHASE3":2412,"PHASE4":2414,"NA":2416},{"trials":2407,"activeCount":94},[],{"trials":2409,"activeCount":94},[],{"trials":2411,"activeCount":94},[],{"trials":2413,"activeCount":94},[],{"trials":2415,"activeCount":94},[],{"trials":2417,"activeCount":94},[2418],{"nctId":2395,"briefTitle":2396,"status":104,"phases":2419,"primaryCompletion":2398,"completion":2398,"start":438,"enrollment":2399,"conditions":2420,"interventions":2421},[87],[2401],[2380,2403],{"intervention":2275,"totalTrials":133,"cells":2423},{"EARLY_PHASE1":2424,"PHASE1":2426,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2434},{"trials":2425,"activeCount":94},[],{"trials":2427,"activeCount":94},[],{"trials":2429,"activeCount":94},[],{"trials":2431,"activeCount":94},[],{"trials":2433,"activeCount":94},[],{"trials":2435,"activeCount":94},[2436],{"nctId":2267,"briefTitle":2268,"status":104,"phases":2437,"primaryCompletion":2270,"completion":2270,"start":2271,"enrollment":2260,"conditions":2438,"interventions":2439},[87],[2273],[2275,2276,2242],{"intervention":2276,"totalTrials":133,"cells":2441},{"EARLY_PHASE1":2442,"PHASE1":2444,"PHASE2":2446,"PHASE3":2448,"PHASE4":2450,"NA":2452},{"trials":2443,"activeCount":94},[],{"trials":2445,"activeCount":94},[],{"trials":2447,"activeCount":94},[],{"trials":2449,"activeCount":94},[],{"trials":2451,"activeCount":94},[],{"trials":2453,"activeCount":94},[2454],{"nctId":2267,"briefTitle":2268,"status":104,"phases":2455,"primaryCompletion":2270,"completion":2270,"start":2271,"enrollment":2260,"conditions":2456,"interventions":2457},[87],[2273],[2275,2276,2242],{"intervention":2459,"totalTrials":133,"cells":2460},"Oxygen",{"EARLY_PHASE1":2461,"PHASE1":2463,"PHASE2":2465,"PHASE3":2467,"PHASE4":2469,"NA":2471},{"trials":2462,"activeCount":94},[],{"trials":2464,"activeCount":94},[],{"trials":2466,"activeCount":94},[],{"trials":2468,"activeCount":94},[],{"trials":2470,"activeCount":94},[],{"trials":2472,"activeCount":94},[2473],{"nctId":2474,"briefTitle":2475,"status":104,"phases":2476,"completion":2477,"start":1297,"enrollment":749,"conditions":2478,"interventions":2480},"NCT00394225","Helium-Hyperoxia and 6MWT Distance in COPD",[87],"2006-05",[2479],"Chronic Obstructive Pulmonary Disease",[2459,2481],"Helium",{"intervention":2481,"totalTrials":133,"cells":2483},{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2488,"PHASE3":2490,"PHASE4":2492,"NA":2494},{"trials":2485,"activeCount":94},[],{"trials":2487,"activeCount":94},[],{"trials":2489,"activeCount":94},[],{"trials":2491,"activeCount":94},[],{"trials":2493,"activeCount":94},[],{"trials":2495,"activeCount":94},[2496],{"nctId":2474,"briefTitle":2475,"status":104,"phases":2497,"completion":2477,"start":1297,"enrollment":749,"conditions":2498,"interventions":2499},[87],[2479],[2459,2481],{"intervention":2501,"totalTrials":133,"cells":2502},"[18F]FDOPA PET\u002FCT",{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2509,"PHASE4":2511,"NA":2513},{"trials":2504,"activeCount":94},[],{"trials":2506,"activeCount":94},[],{"trials":2508,"activeCount":94},[],{"trials":2510,"activeCount":94},[],{"trials":2512,"activeCount":94},[],{"trials":2514,"activeCount":94},[2515],{"nctId":2516,"briefTitle":2517,"status":1903,"phases":2518,"primaryCompletion":2519,"completion":2519,"start":502,"enrollment":2520,"conditions":2521,"interventions":2523},"NCT02538315","Using [18F]FDOPA PET\u002FCT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients",[],"2018-09",18,[2522],"Parkinson's Disease",[2501],{"intervention":2525,"totalTrials":133,"cells":2526},"Local Anesthetics Lidocaine",{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2531,"PHASE3":2533,"PHASE4":2535,"NA":2537},{"trials":2528,"activeCount":94},[],{"trials":2530,"activeCount":94},[],{"trials":2532,"activeCount":94},[],{"trials":2534,"activeCount":94},[],{"trials":2536,"activeCount":94},[],{"trials":2538,"activeCount":94},[2539],{"nctId":2540,"briefTitle":2541,"status":104,"phases":2542,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":2545,"conditions":2546,"interventions":2548},"NCT04833777","Does a Different Local Anesthetic Improve Pain After Carpal Tunnel Release?",[87],"2022-12-01","2021-07-01",140,[2547],"Carpal Tunnel Syndrome",[2525,2549],"Local Anesthetics Bupivacaine",{"intervention":2549,"totalTrials":133,"cells":2551},{"EARLY_PHASE1":2552,"PHASE1":2554,"PHASE2":2556,"PHASE3":2558,"PHASE4":2560,"NA":2562},{"trials":2553,"activeCount":94},[],{"trials":2555,"activeCount":94},[],{"trials":2557,"activeCount":94},[],{"trials":2559,"activeCount":94},[],{"trials":2561,"activeCount":94},[],{"trials":2563,"activeCount":94},[2564],{"nctId":2540,"briefTitle":2541,"status":104,"phases":2565,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":2545,"conditions":2566,"interventions":2567},[87],[2547],[2525,2549],{"intervention":2569,"totalTrials":133,"cells":2570},"General Anesthesia + Spinal anesthesia combined",{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2575,"PHASE3":2577,"PHASE4":2579,"NA":2581},{"trials":2572,"activeCount":94},[],{"trials":2574,"activeCount":94},[],{"trials":2576,"activeCount":94},[],{"trials":2578,"activeCount":94},[],{"trials":2580,"activeCount":94},[],{"trials":2582,"activeCount":94},[2583],{"nctId":2584,"briefTitle":2585,"status":814,"phases":2586,"primaryCompletion":2587,"completion":2587,"start":2588,"enrollment":94,"conditions":2589,"interventions":2591},"NCT01511627","Randomized Controlled Trial Comparing Postoperative Pain Following TAH With GA vs. Combined GA + SAB",[87],"2012-07","2012-01",[2590],"Hysterectomy",[2569,1395],{"intervention":1395,"totalTrials":133,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2596,"PHASE2":2598,"PHASE3":2600,"PHASE4":2602,"NA":2604},{"trials":2595,"activeCount":94},[],{"trials":2597,"activeCount":94},[],{"trials":2599,"activeCount":94},[],{"trials":2601,"activeCount":94},[],{"trials":2603,"activeCount":94},[],{"trials":2605,"activeCount":94},[2606],{"nctId":2584,"briefTitle":2585,"status":814,"phases":2607,"primaryCompletion":2587,"completion":2587,"start":2588,"enrollment":94,"conditions":2608,"interventions":2609},[87],[2590],[2569,1395],{"intervention":2240,"totalTrials":133,"cells":2611},{"EARLY_PHASE1":2612,"PHASE1":2614,"PHASE2":2616,"PHASE3":2618,"PHASE4":2620,"NA":2622},{"trials":2613,"activeCount":94},[],{"trials":2615,"activeCount":94},[],{"trials":2617,"activeCount":94},[],{"trials":2619,"activeCount":94},[],{"trials":2621,"activeCount":94},[],{"trials":2623,"activeCount":94},[2624],{"nctId":2231,"briefTitle":2232,"status":104,"phases":2625,"primaryCompletion":2234,"completion":2234,"start":2235,"enrollment":2236,"conditions":2626,"interventions":2627},[87],[2238,726],[2240,112],{"intervention":2629,"totalTrials":133,"cells":2630},"0.15mg desogestrel \u002F0.03mg ethinyl estradiol",{"EARLY_PHASE1":2631,"PHASE1":2633,"PHASE2":2635,"PHASE3":2637,"PHASE4":2639,"NA":2641},{"trials":2632,"activeCount":94},[],{"trials":2634,"activeCount":94},[],{"trials":2636,"activeCount":94},[],{"trials":2638,"activeCount":94},[],{"trials":2640,"activeCount":94},[],{"trials":2642,"activeCount":94},[2643],{"nctId":2644,"briefTitle":2645,"status":104,"phases":2646,"completion":2647,"start":2648,"enrollment":2649,"conditions":2650,"interventions":2651},"NCT00204438","Administration of Oral Contraceptives at Different Times of the Follicular Phase of the Menstrual Cycle",[87],"2002-12","2002-02",45,[1299],[2629],{"intervention":2653,"totalTrials":133,"cells":2654},"Chlorhexidine",{"EARLY_PHASE1":2655,"PHASE1":2657,"PHASE2":2659,"PHASE3":2661,"PHASE4":2663,"NA":2665},{"trials":2656,"activeCount":94},[],{"trials":2658,"activeCount":94},[],{"trials":2660,"activeCount":94},[],{"trials":2662,"activeCount":94},[],{"trials":2664,"activeCount":94},[],{"trials":2666,"activeCount":94},[2667],{"nctId":2668,"briefTitle":2669,"status":104,"phases":2670,"primaryCompletion":2671,"completion":1246,"start":2672,"enrollment":2673,"conditions":2674,"interventions":2678},"NCT00223002","Chlorhexidine Versus Povidone-Iodine for Prevention of Epidural Needle Contamination in the Parturient",[87],"2007-01","2004-11",400,[2675,2676,2677],"Asepsis","Analgesia, Epidural","Anesthesia, Epidural",[2653],{"intervention":2680,"totalTrials":133,"cells":2681},"PT plus translingual stimulation device",{"EARLY_PHASE1":2682,"PHASE1":2684,"PHASE2":2686,"PHASE3":2688,"PHASE4":2690,"NA":2692},{"trials":2683,"activeCount":94},[],{"trials":2685,"activeCount":94},[],{"trials":2687,"activeCount":94},[],{"trials":2689,"activeCount":94},[],{"trials":2691,"activeCount":94},[],{"trials":2693,"activeCount":94},[2694],{"nctId":2695,"briefTitle":2696,"status":525,"phases":2697,"primaryCompletion":2698,"completion":2543,"start":2699,"enrollment":2700,"conditions":2701,"interventions":2702},"NCT05275049","Neuromodulation in MS Using Translingual Stimulation",[87],"2022-07-05","2021-07-05",52,[32],[2680,2703],"PT plus translingual stimulation control device",{"intervention":2703,"totalTrials":133,"cells":2705},{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2714,"NA":2716},{"trials":2707,"activeCount":94},[],{"trials":2709,"activeCount":94},[],{"trials":2711,"activeCount":94},[],{"trials":2713,"activeCount":94},[],{"trials":2715,"activeCount":94},[],{"trials":2717,"activeCount":94},[2718],{"nctId":2695,"briefTitle":2696,"status":525,"phases":2719,"primaryCompletion":2698,"completion":2543,"start":2699,"enrollment":2700,"conditions":2720,"interventions":2721},[87],[32],[2680,2703],{"intervention":2723,"totalTrials":133,"cells":2724},"Lidocaine infusion plus ketamine",{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2729,"PHASE3":2731,"PHASE4":2733,"NA":2735},{"trials":2726,"activeCount":94},[],{"trials":2728,"activeCount":94},[],{"trials":2730,"activeCount":94},[],{"trials":2732,"activeCount":94},[],{"trials":2734,"activeCount":94},[],{"trials":2736,"activeCount":94},[2737],{"nctId":2738,"briefTitle":2739,"status":1903,"phases":2740,"completion":2741,"start":2742,"enrollment":1341,"conditions":2743,"interventions":2744},"NCT00229567","Intra-op Lidocaine and Ketamine Effect on Postoperative Bowel Function",[87],"2006-11","2005-09",[309],[2723],{"intervention":2746,"totalTrials":133,"cells":2747},"Methacholine challenge",{"EARLY_PHASE1":2748,"PHASE1":2750,"PHASE2":2752,"PHASE3":2754,"PHASE4":2756,"NA":2758},{"trials":2749,"activeCount":94},[],{"trials":2751,"activeCount":94},[],{"trials":2753,"activeCount":94},[],{"trials":2755,"activeCount":94},[],{"trials":2757,"activeCount":94},[],{"trials":2759,"activeCount":94},[2760],{"nctId":2761,"briefTitle":2762,"status":104,"phases":2763,"primaryCompletion":2764,"completion":2764,"start":2765,"enrollment":475,"conditions":2766,"interventions":2767},"NCT00890539","Methacholine Challenge: Comparison of Doubling and Quadrupling Methacholine Dose Regimes Using the Tidal Volume Method",[87],"2009-03","2009-02",[15],[2746],{"intervention":2769,"totalTrials":133,"cells":2770},"Montelukast",{"EARLY_PHASE1":2771,"PHASE1":2773,"PHASE2":2775,"PHASE3":2777,"PHASE4":2779,"NA":2781},{"trials":2772,"activeCount":94},[],{"trials":2774,"activeCount":94},[],{"trials":2776,"activeCount":94},[],{"trials":2778,"activeCount":94},[],{"trials":2780,"activeCount":94},[],{"trials":2782,"activeCount":94},[2783],{"nctId":2784,"briefTitle":2785,"status":104,"phases":2786,"primaryCompletion":2787,"completion":2787,"start":2671,"enrollment":201,"conditions":2788,"interventions":2789},"NCT00424580","Airway Responses to Montelukast and Desloratadine.",[87],"2007-08",[15],[2769],{"intervention":2791,"totalTrials":133,"cells":2792},"Aliquoted allogeneic donor plasma in patient's conjunctiva",{"EARLY_PHASE1":2793,"PHASE1":2795,"PHASE2":2797,"PHASE3":2799,"PHASE4":2801,"NA":2803},{"trials":2794,"activeCount":94},[],{"trials":2796,"activeCount":94},[],{"trials":2798,"activeCount":94},[],{"trials":2800,"activeCount":94},[],{"trials":2802,"activeCount":94},[],{"trials":2804,"activeCount":94},[2805],{"nctId":2806,"briefTitle":2807,"status":525,"phases":2808,"primaryCompletion":2809,"completion":1042,"start":2810,"enrollment":133,"conditions":2811,"interventions":2813},"NCT05404932","Treatment of Ligneous Conjunctivitis in Children With Plasminogen Deficiency",[87],"2024-09-30","2022-12-15",[2812],"Plasminogen Deficiency",[2791],{"intervention":2815,"totalTrials":133,"cells":2816},"Ropivacaine 0.5% Injectable Solution",{"EARLY_PHASE1":2817,"PHASE1":2819,"PHASE2":2821,"PHASE3":2823,"PHASE4":2825,"NA":2827},{"trials":2818,"activeCount":94},[],{"trials":2820,"activeCount":94},[],{"trials":2822,"activeCount":94},[],{"trials":2824,"activeCount":94},[],{"trials":2826,"activeCount":94},[],{"trials":2828,"activeCount":94},[2829],{"nctId":2830,"briefTitle":2831,"status":104,"phases":2832,"primaryCompletion":2833,"completion":2833,"start":2834,"enrollment":2835,"conditions":2836,"interventions":2840},"NCT03563963","Ropivacaine vs Lidocaine in the Endotracheal Tube Cuff on Post-Operative Sore Throat",[87],"2018-09-30","2018-08-01",63,[2837,1406,701,2838,2839],"Pharyngitis","Intubation, Intratracheal","Post-operative Sore Throat",[2815,2841],"Lidocaine 2% Preservative-Free Injectable Solution",{"intervention":2841,"totalTrials":133,"cells":2843},{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2854},{"trials":2845,"activeCount":94},[],{"trials":2847,"activeCount":94},[],{"trials":2849,"activeCount":94},[],{"trials":2851,"activeCount":94},[],{"trials":2853,"activeCount":94},[],{"trials":2855,"activeCount":94},[2856],{"nctId":2830,"briefTitle":2831,"status":104,"phases":2857,"primaryCompletion":2833,"completion":2833,"start":2834,"enrollment":2835,"conditions":2858,"interventions":2859},[87],[2837,1406,701,2838,2839],[2815,2841],{"intervention":2861,"totalTrials":133,"cells":2862},"ibuprofen",{"EARLY_PHASE1":2863,"PHASE1":2865,"PHASE2":2867,"PHASE3":2869,"PHASE4":2871,"NA":2873},{"trials":2864,"activeCount":94},[],{"trials":2866,"activeCount":94},[],{"trials":2868,"activeCount":94},[],{"trials":2870,"activeCount":94},[],{"trials":2872,"activeCount":94},[],{"trials":2874,"activeCount":94},[2875],{"nctId":2876,"briefTitle":2877,"status":104,"phases":2878,"primaryCompletion":2234,"completion":2234,"start":2879,"enrollment":154,"conditions":2880,"interventions":2882},"NCT02327234","Airway Response to Repeat Allergen Challenge and the Effect of Ibuprofen in Mild Atopic Asthma",[87],"2014-12",[2881],"Atopic Asthma",[2861]]